Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT – Get Free Report)’s stock price rose 1% during trading on Thursday . The stock traded as high as $0.12 and last traded at $0.12. Approximately 42,939 shares traded hands during trading, a decline of 75% from the average daily volume of 173,214 shares. The stock had previously closed at $0.12.
Provectus Biopharmaceuticals Trading Down 2.4 %
The business has a 50-day moving average price of $0.12 and a two-hundred day moving average price of $0.11.
Provectus Biopharmaceuticals Company Profile
Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.
Featured Stories
- Five stocks we like better than Provectus Biopharmaceuticals
- 3 REITs to Buy and Hold for the Long Term
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- Why is the Ex-Dividend Date Significant to Investors?
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Transportation Stocks Investing
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for Provectus Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provectus Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
-inc-logo-1200x675.PNG?v=20210312142656&h=45&w=95&zc=2){kind=logo}
